PMID- 38448878
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240309
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Mar 6
TI  - Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung 
      cancer: a systematic review.
PG  - 312
LID - 10.1186/s12885-024-12043-w [doi]
LID - 312
AB  - BACKGROUND: There are differences in the pharmacoeconomics of Immune checkpoint 
      blocking (ICB) therapies for the treatment of lung squamous cell carcinoma 
      (LSCC). However, no corresponding review studies have fully discussed the 
      cost-effectiveness of ICBs in treating LSCC. The aim of this paper is to 
      systematically review and evaluate all available pharmacoeconomic studies of ICBs 
      for LSCC. METHOD: The inclusion criteria were based on the population, 
      intervention, comparator, outcomes, and study designs. An electronic search was 
      conducted by June 2023, and the following databases were used: PubMed, EMBASE, 
      Cochrane Library, and Web of Science. Search keywords included 'Carcinoma', 
      Non-Small-Cell Lung', 'Immunotherapy', and 'Economics, Medical'. The primary 
      outcome was the cost-effectiveness analysis of ICB therapy in LSCC patients. 
      Drummond Checklist was used to assess quality problems and possible bias in the 
      study design of included pharmacoeconomic studies. RESULTS: This review searched 
      15 articles on the economic evaluation of ICB treatment for LSCC. After a 
      qualitative review of 15 studies, we concluded that nivolumab is more 
      cost-effective as a monotherapy than chemotherapy alone. In the combination 
      regimen, pembrolizumab combined with chemotherapy appears to be the most 
      cost-effective option at present, but for Chinese payers with LSCC, locally 
      developed treatments such as sintilimab or toripalimab in combination with 
      chemotherapy are more cost-effective. DISCUSSION: The inclusion of economic 
      evaluation has heterogeneity in research design and outcomes, which can only 
      support qualitative synthesis. Therefore, The results of this paper need to be 
      treated with caution. For the Chinese market, instead of imported drugs, the 
      possible cost-effectiveness of locally developed ICB therapies should be the 
      focus of future research.
CI  - (c) 2024. The Author(s).
FAU - Cheng, Minyu
AU  - Cheng M
AD  - Department of Pharmacy, Zhejiang Hospital, 310013, Hangzhou, China.
FAU - Shao, Yanfei
AU  - Shao Y
AD  - Department of Pharmacy, Zhejiang Provincial People's Hospital, 310014, Hangzhou, 
      China.
FAU - Li, Li
AU  - Li L
AD  - Department of Pharmacy, Zhejiang Hospital, 310013, Hangzhou, China.
FAU - Jiang, Menglao
AU  - Jiang M
AD  - Zhejiang Center of Drug and Cosmetics Evaluation, 310000, Hangzhou, Zhejiang, 
      China.
FAU - Song, Zhouye
AU  - Song Z
AD  - Department of Pharmacy, Zhejiang Hospital, 310013, Hangzhou, China. 
      szy1066@126.com.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20240306
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Cost-Benefit Analysis
MH  - Cost-Effectiveness Analysis
MH  - *Lung Neoplasms/drug therapy
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - Immunotherapy
PMC - PMC10916025
OTO - NOTNLM
OT  - Camrelizumab
OT  - Cost-effectiveness
OT  - Immunotherapy
OT  - Nivolumab
OT  - Non-small cell lung cancer
OT  - Pembrolizumab
OT  - Sintilimab
OT  - Sugemalimab
OT  - Toripalimab
COIS- The authors declare that they have no competing interests.
EDAT- 2024/03/07 00:43
MHDA- 2024/03/08 06:43
PMCR- 2024/03/06
CRDT- 2024/03/06 23:40
PHST- 2023/10/24 00:00 [received]
PHST- 2024/02/22 00:00 [accepted]
PHST- 2024/03/08 06:43 [medline]
PHST- 2024/03/07 00:43 [pubmed]
PHST- 2024/03/06 23:40 [entrez]
PHST- 2024/03/06 00:00 [pmc-release]
AID - 10.1186/s12885-024-12043-w [pii]
AID - 12043 [pii]
AID - 10.1186/s12885-024-12043-w [doi]
PST - epublish
SO  - BMC Cancer. 2024 Mar 6;24(1):312. doi: 10.1186/s12885-024-12043-w.